Skip to content
Screener

Kestra Medical Technologies KMTS Q2 2026 earnings

Reported December 11, 2025 · After market close

Revenue$22.6MMiss by $306.7K
EPS-$0.62Miss by $0.03
Revenue estimate$22.9M
EPS estimate-$0.59

Next report

Dec 10, 2026 (in 2 months)
Revenue estimate$32.0M
EPS estimate-$0.61

Financials

Q2 2026

Income statement

See full
Revenue$22.6M+53.4%
Gross profit$11.4M+96.0%
Operating income-$31.8M-66.0%
Net income-$32.8M-61.0%
EPS (diluted)-$0.64+46.2%

Balance sheet

See full
Cash & equivalents$175.4M+128%
Total debt$44.8M—
Total assets$246.7M—

Cash flow

See full
Operating cash flow-$18.3M-1.6%
CapEx$7.3M+63.4%
Free cash flow-$25.6M-13.8%

Valuation & ratios

Valuation

as of 10/31/25
See full
Market cap$1.41B—
Enterprise value$1.28B—
P/S19×—

Profitability

See full
Gross margin46.4%+21.7pp
Operating margin-174.3%-15.7pp
Net margin-178%-24.0pp
FCF margin-152.9%-34.5pp

Returns & leverage

See full
Current ratio5.5×—

FAQ

When did Kestra Medical Technologies report Q2 2026 earnings?
Kestra Medical Technologies (KMTS) reported Q2 2026 earnings on December 11, 2025 after market close.
What were Kestra Medical Technologies's Q2 2026 revenue and EPS?
Kestra Medical Technologies reported revenue of $22.6M and eps of $-0.62 for Q2 2026.
Did Kestra Medical Technologies beat estimates in Q2 2026?
Revenue missed the consensus estimate of $22.9M by $306.7K. EPS missed the consensus estimate of $-0.59 by $0.03.
Where can I find Kestra Medical Technologies's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-25-315896) and the 10-Q periodic report (0001193125-25-316210) directly on SEC EDGAR. The filing index links above go to sec.gov.